WallStreetZenWallStreetZen

NASDAQ: BMRN
Biomarin Pharmaceutical Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

BMRN past earnings growth

How has BMRN's earnings growth performed historically?
Company
71.11%
Industry
17.58%
Market
40.82%
BMRN's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
BMRN's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
BMRN's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

BMRN past revenue growth

How has BMRN's revenue growth performed historically?
Company
15.05%
Industry
109.79%
Market
14.13%
BMRN's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
BMRN's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
BMRN's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

BMRN earnings and revenue history

Current Revenue
$2.3B
Current Earnings
$147.0M
Current Profit Margin
6.4%

BMRN Return on Equity

Current Company
3.1%
Current Industry
15.7%
Current Market
-9.5%
BMRN's Return on Equity (3.1%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when BMRN announces earnings.

BMRN Return on Assets

Current Company
2.3%
Current Industry
2.2%
BMRN is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

BMRN Return on Capital Employed

Current Company
2.98%
Current Industry
17.7%
BMRN has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

BMRN vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
BMRN$2.31B$268.62M$147.02M+9.08%-94.22%
RPRX$2.32B$371.30M$184.41M+54.02%-55.16%
BGNE$2.20B-$900.11M-$959.49M+69.47%N/A
GMAB$2.42BN/A$611.10M+45.73%+26.83%
ALNY$1.72B-$285.11M-$509.87M+79.77%N/A
View Top Biotech Stocks

Biomarin Pharmaceutical Earnings & Revenue FAQ

What were BMRN's earnings last quarter?

On Invalid Date, Biomarin Pharmaceutical (NASDAQ: BMRN) reported Q3 2023 earnings per share (EPS) of $0.21, up 625% year over year. Total Biomarin Pharmaceutical earnings for the quarter were $40.38 million. In the same quarter last year, Biomarin Pharmaceutical's earnings per share (EPS) was -$0.04.

If you're new to stock investing, here's how to buy Biomarin Pharmaceutical stock.

What was BMRN's earnings growth in the past year?

As of Q4 2023, Biomarin Pharmaceutical's earnings has grown 71.11% year over year. This is 53.53 percentage points higher than the US Biotechnology industry earnings growth rate of 17.58%. Biomarin Pharmaceutical's earnings in the past year totalled $147.02 million.

What was BMRN's revenue last quarter?

On Invalid Date, Biomarin Pharmaceutical (NASDAQ: BMRN) reported Q3 2023 revenue of $581.33 million up 15.04% year over year. In the same quarter last year, Biomarin Pharmaceutical's revenue was $505.34 million.

What was BMRN's revenue growth in the past year?

As of Q4 2023, Biomarin Pharmaceutical's revenue has grown 15.05% year over year. This is 94.74 percentage points lower than the US Biotechnology industry revenue growth rate of 109.79%. Biomarin Pharmaceutical's revenue in the past year totalled $2.31 billion.
©2023 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.